Alkermes Plc. Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Alkermes Plc. is a global biopharmaceutical company focused on neuroscience, commercializing proprietary products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company operates as a single segment. Notable corporate actions in the period included the completion of the sale of its Athlone, Ireland facility to Novo Nordisk in May 2024 and the ongoing separation of its former oncology business (Mural Oncology), which is reported as discontinued operations.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenues | $378.1 million | $380.9 million | $1,127.6 million | $1,285.9 million |
| Net Income (Continuing Ops) | $92.8 million | $91.6 million | $226.4 million | $358.6 million |
| Diluted EPS (Continuing Ops) | $0.56 | $0.53 | $1.33 | $2.10 |
| Operating Cash Flow (YTD) | $248.7 million (2024) vs $294.1 million (2023) | |||
| Cash & Investments (Total) | $927.8 million (as of Sept 30, 2024) | |||
| Long-Term Debt | $285.8 million (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Revenue Composition: Total revenue decreased slightly in Q3 2024 compared to Q3 2023, driven by a $44.0 million decrease in manufacturing and royalty revenues. This decline is primarily attributed to the expiration of royalties on INVEGA SUSTENNA in August 2024 and the absence of the $195.4 million in back-royalties received in June 2023 following the Janssen arbitration settlement.
- Product Sales Growth: Net product sales increased by $41.2 million in Q3 2024. This was driven by strong growth in LYBALVI (up 47% QoQ) and VIVITROL (up 14% QoQ), partially offset by modest growth in ARISTADA.
- Expense Management: Operating expenses decreased by $18.4 million in Q3 2024 compared to the prior year, reflecting disciplined cost controls in R&D and SG&A, including headcount reductions in sales and marketing.
- Tax Provision: The income tax provision increased significantly to $17.4 million in Q3 2024 (from $1.2 million in Q3 2023) due to taxes on income earned in Ireland and the impact of the global minimum tax (Pillar Two).
- Share Repurchases: The company repurchased approximately 4.4 million shares in Q3 2024 for $115.3 million under its new $400 million program. As of period end, $200.0 million remained authorized.
Guidance, Outlook, and Risks
- Outlook: Management expects royalty revenues from long-acting INVEGA products to decrease in the near-term following the expiration of the INVEGA SUSTENNA royalty in August 2024. The company anticipates existing cash and investments will be sufficient to fund operations for at least the next 12 months.
- Development Pipeline: R&D spending increased for ALKS 2680 (narcolepsy/hypersomnia) due to the initiation of Phase 2 studies. The company expects to initiate a Phase 2 study for idiopathic hypersomnia in 2025.
- Legal & Regulatory Risks:
- Patent Litigation: Ongoing Paragraph IV litigation regarding generic versions of INVEGA TRINZA and VUMERITY poses risks to future royalty and product sales.
- Government Investigations: The company is cooperating with subpoenas and civil investigative demands from U.S. authorities regarding VIVITROL.
- Product Liability: Active defense of a product liability case alleging inadequate VIVITROL labeling.
- Discontinued Operations: The oncology business (Mural Oncology) was separated in November 2023. Results are reported as discontinued operations, with a net loss of $0.4 million in Q3 2024.
Investor Verification Checklist
- INVEGA Royalty Run-Rate: Verify the specific impact of the INVEGA SUSTENNA royalty expiration on future quarterly revenue projections.
- LYBALVI Growth Sustainability: Assess the drivers behind the 59% gross sales increase for LYBALVI and potential market saturation or competitive pressures.
- Share Repurchase Impact: Confirm the remaining $200 million authorization and the company's commitment to capital return versus R&D investment.
- Legal Exposure: Review the status of the VUMERITY ANDA litigation (trial scheduled for July 2025) and the VIVITROL government investigations for potential financial accruals.
- ALKS 2680 Progress: Monitor upcoming data readouts from the Vibrance-1 and Vibrance-2 Phase 2 studies for narcolepsy.